Myelodysplastic Syndromes

More documents

Recommendations

Info

The patient is 62 year old man who presents with increasing fatigue and bruising over several months. The patient is on no medications. CBC analysis shows: WBC 2.7 x10 9 /L; Neuts 1.1 x10 9 /L HGB 9.1 g/dL MCV 96 fl PLTS 47x10E9/L Cytogenetics: Normal Ring sideroblasts: − MDS − Alcohol/toxins − Drugs (e.g. INH) − Zinc toxicity − Copper deficiency − Pyridoxine deficiency − Congenital sideroblastic anemia − Mitochondrial cytopathy (Pearson syndrome) In this case, features suggest copper deficiency (in some cases due to zinc toxicity) RARS 9 year old girl presenting with fever and pancytopenia Hemophagocytic lymphohistiocytosis (HLH); dysplasia may be cytokine related 6
MDS cytogenetics Presumptive diagnosis in patients with persistent cytopenias of undetermined origin but lacking diagnostic morphologic dysplasia (should be followed for definitive dysplasia before unequivocal dx) *Alone NOT considered definitive evidence for MDS (in absence of dysplasia): +8 del(20q) Abnormality Frequency (diagnosis) Unbalanced -7 or del(7q) 10% (50% t-MDS) -5 or del(5q) 10% (40% t-MDS) +8* 10% del(20q)* 5-8% -Y* 5% i(17q) or t(17p) 3-5% del(11q) 3% del(12p) or t(12p) 3% -13 or del(13q) 3% del(9q) 1-2% idic(X)(q13) 1-2% Balanced t(11;16)(q23;p13.3) (3% t-MDS) t(3;21)(q26.2;q22.1) (2% t-MDS) t(1;3)(p36.3;q21.2) 1% t(2;11)(p21;q23) 1% inv(3)(q21;q26.2) 1% t(6;9)(p23;q34) 1% -Y WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008. Flow Cytometry in MDS • Presently not routinely used for diagnosis or classification • Evaluation of previously diagnosed MDS by highly experienced flow labs with numerous myeloid markers and objective criteria for “abnormal” show: • Sensitivity: ~70-90% • Specificity: ~90% • ~10% flow abnormal with non-diagnostic morphology and cytogenetics – Insufficient data to determine whether these biologically behave like MDS (true or false pos?) FISH Analysis • Panels often include -5/del(5q), -7/del(7q), +8, and del(20q) • FISH correlates with karyotypic findings • FISH detects few (0-6%) additional abnormalities if karyotype is adequate and generally not needed in this setting • FISH useful if: – suboptimal metaphase analysis; detects up to 15% more abnormalities – morphology suggests a specific abnormality that was not detected by cytogenetics • Sensitivity for residual disease following treatment is not much better than routine karyotype Flow Cytometry in MDS Cautions • Reactive conditions (marrow recovery, G-CSF therapy, infection) can cause mild phenotypic alterations. • Insufficient literature to fully understand myeloid phenotypic change in reactive conditions that may mimic MDS • Blast assessment can be useful, but...morphologic blast count required for diagnosis and classification because: – Some blasts do not express stem cell antigens (CD34, CD117) – Processing for flow lyses erythroid precursors – Blasts can be fragile with a subset lost during processing 7
Page 1 and 2: Myelodysplastic Syndromes Joan E. E
Page 3 and 4: WHO MDS Classification • Dysplasi
Page 5: Neutrophil dysplasia • Hypo-, agr
Page 9 and 10: Hypocellular MDS • Proper classif
Page 11 and 12: Paryoxysmal Nocturnal Hemoglobinuri
Page 13 and 14: The patient is a 32 year old taxi d
Page 15: The patient is a 56 year old man wh

Myelodysplastic Syndromes

Create successful ePaper yourself

Delete template?

Save as template?